Lisa A. Jackson, MD, MPH

“Group Health gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”

Lisa A. Jackson, MD, MPH

Group Health Research Institute Senior Investigator
Group Health Physician

Biography

Lisa A. Jackson is an internist and infectious disease epidemiologist who has spent the past 20 years conducting clinical and epidemiologic studies of vaccine safety and efficacy.

In addition to her role as a senior scientific investigator at Group Health Research Institute (GHRI), she is a research professor in the University of Washington (UW) Department of Epidemiology and an adjunct research professor in the UW Department of Medicine

 Dr. Jackson is the principal investigator (PI) at Group Health of the Vaccine Safety Datalink Project sponsored by the Centers for Disease Control and Prevention. She is also PI of the Vaccine and Treatment Evaluation Unit hosted by GHRI, one of eight such facilities nationwide that are sponsored by the National Institutes of Health.

Dr. Jackson has authored more than 140 peer-reviewed publications and 14 book chapters.  She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Advisory Committee.

Dr. Jackson received her medical degree from the University of Virginia School of Medicine, Charlottesville, and her master of public health degree from the University of Washington School of Public Health and Community Medicine.

Research interests and experience

  • Vaccines & Infectious Diseases

    Vaccine  safety; influenza vaccine effectiveness in the elderly; methodologic issues in  vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine  effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly;  epidemiology of E. coli bacteremia; epidemiology of community-acquired  pneumonia

 

Recent publications

Zimmerman RK, Nowalk MP, Chung J, Jackson ML, Jackson LA, Petrie JG, Monto AS, McLean HQ, Belongia EA, Gaglani M, Murthy K, Fry AM, Flannery B. 2014-2015 influenza vaccine effectiveness in the United States by vaccine type. Clin Infect Dis. 2016 Oct 4. pii: ciw635. [Epub ahead of print]. PubMed

Flannery B, Zimmerman RK, Gubareva LV, Garten RJ, Chung JR, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Ohmit SE, Belongia EA, McLean HQ, Gaglani M, Piedra PA, Mishin VP, Chesnokov AP, Spencer S, Thaker SN, Barnes JR, Foust A, Sessions W, Xu X, Katz J, Fry AM. Enhanced genetic characterization of influenza A(H3N2) viruses and vaccine effectiveness by genetic group, 2014-2015. J Infect Dis. 2016 May 6. pii: jiw181. [Epub ahead of print]. PubMed

Jackson ML, Bellamy A, Wolff M, Hill H, Jackson LA. Low-dose aspirin use does not diminish the immune response to monovalent H1N1 influenza vaccine in older adults. Epidemiol Infect. 2016 Mar;144(4):768-71. doi: 10.1017/S0950268815002058. Epub 2015 Sep 2. PubMed

Zimmerman RK, Balasubramani GK, Nowalk MP, Eng H, Urbanski L, Jackson ML, Jackson LA, McLean HQ, Belongia EA, Monto AS, Malosh RE, Gaglani M, Clipper L, Flannery B, Wisniewski SR. Classification and Regression Tree (CART) analysis to predict influenza in primary care patients. BMC Infect Dis. 2016 Sep 22;16(1):503. PubMed

 

healthy findings blog

Biomed company and GHRI test new device for collecting blood

The GHRI-industry collaboration will study sample collection for lab tests, writes Clinical Research Director Tricia Buscio.

Read it in Healthy Findings.

Vaccines & Infectious Diseases

Immune response to bird flu vaccine is boosted by adjuvants

Vaccine Treatment and Evaluation Unit tests real-world use to prepare for H7N9.

Read it in News and Events.

GHRI In the Media

Immune response to bird flu vaccine is boosted by adjuvants

Bird-flu vaccine needs a boost, Seattle researchers find

The Seattle Times, July 21, 2015